Payer Transparency Reforms: Moving From Rebates To Drug Access Restrictions

Institute for Clinical and Economic Review analysis of whether payers are providing ‘fair access’ to fairly priced drugs was hampered by a lack of transparency among payers, leading to calls for reform.

Drug pricing transparency (Nielsen Hobbs; the Pink Sheet | Alamy images)
Shining more light on pricing Could Ensure Fair Access To Drugs, ICER Says • Source: Nielsen Hobbs; the Pink Sheet | Alamy images

More from Market Access

More from Pink Sheet